Trial Profile
Evaluation of Efficacy of Denosumab in Adult Patients With Langerhans Cell Histiocytosis (LCH): a Multiple-site, Single Arm, Open Label Clinical Trial
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Dec 2022
Price :
$35
*
At a glance
- Drugs Denosumab (Primary)
- Indications Langerhans cell histiocytosis
- Focus Therapeutic Use
- 01 Oct 2022 Status changed from active, no longer recruiting to completed.
- 27 Nov 2020 Planned End Date changed from 30 Sep 2021 to 30 Sep 2022.
- 27 Nov 2020 Planned primary completion date changed from 30 May 2021 to 30 May 2022.